In response to this challenge, sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are recommended for managing cardiovascular risk in patients with diabetic ASCVD (58). This evidence concerns the gene GLP1R and atherosclerosis.